Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Shares Outstanding (Weighted Average) (2016 - 2025)

Traws Pharma's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $8.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $8.2 million for Q4 2025, up 429.93% from a year ago — trailing twelve months through Dec 2025 was $8.2 million (up 429.93% YoY), and the annual figure for FY2025 was $8.2 million, up 429.93%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $8.2 million at Traws Pharma, down from $8.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $20.9 million in Q4 2022 to a low of $346180.0 in Q3 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $986980.0 (2024), against an average of $5.2 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 3922.14% in 2022, then plummeted 98.31% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $16.8 million in 2021, then rose by 24.22% to $20.9 million in 2022, then crashed by 95.98% to $839554.0 in 2023, then skyrocketed by 84.94% to $1.6 million in 2024, then surged by 429.93% to $8.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $8.2 million, $8.8 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.